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Background: Novel antidepressant drugs are 
increasingly used by women of child bearing age. 
However, potentially harmful effects on fetus and 
newborn remain unknown.
Methods: Case report and literature review.
Results: We present preterm twins whose mother was 
treated with venlafaxine, a nonselective serotonin reuptake 
inhibitor, throughout pregnancy until delivery. The twins 
developed neonatal necrotizing enterocolitis.
Conclusion: The question whether there might be 
a correlation between maternal serotonin reuptake 
inhibitor therapy and neonatal necrotizing enterocolitis is 
discussed.
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Introduction
Venlafaxine (Efexor®) is a nonselective serotonin reuptake inhibitor (nSSRI). It is supposedly a potent serotonin and norepinephrine reuptake 
inhibitor and a weak inhibitor of dopamine reuptake. It 
is commonly used in the therapy of depression and panic 
disorders. Venlafaxine is metabolized in the liver and is 
mainly eliminated by the kidneys. In adults the average 
elimination half life of venlafaxine is 5 hours and that of 
its active metabolite O-desmethylvenlafaxine 11 hours. 
In neonates the elimination half life is unknown.
Reproduction studies in rats and rabbits given 
venlafaxine at doses up to 2.5 to 4 times the maximum 
recommended human daily dose did not reveal 
teratogenicity.[1] When rats were given the maximum 
dose during pregnancy through weaning, there was 
a decrease in pup weight and an elevated number of 
stillbirths and pup deaths during the fi rst 5 days of 
lactation.[1]
Einarson et al[2] compared 150 pregnant women 
using venlafaxine to 150 women exposed to selective 
serotonin reuptake inhibitors (SSRIs) and 150 women 
exposed to nonteratogenic agents. There were no 
signifi cant differences in the rate of abortions, 
gestational age at birth, live births, birth weights, 
and major malformations. Withdrawal symptoms of 
newborn infants after exposure to SSRI and nSSRI are 
well-described.[3,4]
Case report
We present dichorial diamniotic twins who both 
developed necrotizing enterocolitis (NEC) on the 6th 
day of life. They were delivered by cesarean section 
at a gestational age of 33+2 weeks due to persistent 
vaginal bleeding and contractions secondary to 
placenta praevia marginalis. The fi rst two trimesters 
of pregnancy were uneventful. The mother was 
hospitalized for the fi rst time in the 31st week of 
pregnancy because of vaginal bleeding. Because of 
an infection with Chlamydia trachomatis, she was 
treated with azithromycin (zithromax®) for 4 days. 
She received betamethasone (celestone chondrose®) 12 
mg twice in 24 hours to enhance fetal lung maturity. 
Furthermore the mother was treated with venlafaxine 
(Efexor®) throughout pregnancy at a single dosage of 
75 mg per day until delivery because of depression.
Twin A was born with a birthweight of 1700 g (15th 
percentile). He had Apgar scores of 6 at 1 minute, 7 at 
5 minutes, and 8 at 10 minutes. The umbilical arterial 
cord pH was 7.22.
The baby was intubated in the fi rst hour of life 
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because of respiratory insuffi ciency and supplemental 
oxygen requirement. He was extubated successfully 
on the second day of life. Feeding was started on the 
fi rst postnatal day with maltodextrin® and breast milk. 
Enteral feeds with breast milk and preterm formula 
were gradually increased by about 20 ml/kg per day 
until the feeding volume reached 100 ml/kg per day on 
the 5th postnatal day.
On the 6th day of life, the child showed signs 
of necrotizing enterocolitis (NEC) with abdominal 
distension and bloody stool. Conservative management 
consisted of withholding oral feeds for 3 days and 
intravenous antibiotics, amikacine and amoxicilline 
for 5 and 7 days, respectively. Apart from clostridium 
diffi cile toxin in the stool specimen, blood and stool 
cultures were negative. The abdominal X-ray revealed 
no signs of pneumoperitoneum or pneumatosis 
intestinalis (Bell's stage I). Feeds were well-tolerated 
afterwards. 
Twin B was born with a birthweight of 1980 g (30th 
percentile). He had Apgar scores of 4 at 1 minute, 5 at 
5 minutes, and 8 at 10 minutes. The umbilical arterial 
cord pH was 7.24.
Twin B was also ventilated on his fi rst day of life 
for respiratory insuffi ciency and supplemental oxygen 
requirement. Enteral feeds were also started on the 
fi rst day of life with maltodextrin® and breast milk. As 
in twin A, enteral feeds with breast milk and preterm 
formula were gradually increased by about 20 ml/kg 
per day until the feeding volume reached 80 ml/kg per 
day on the 5th postnatal day.
On the 6th day, he developed abdominal distension, 
signs of peritonitis, bloody stool and gastric residuals. 
Conservative therapy with intravenous antibiotics 
(amikacine and amoxicilline) and stop of oral feeding 
was initiated. The abdominal X-ray showed intestinal 
pneumatosis, but no pneumoperitoneum (Bell's stage 
IIb). Because of further clinical deterioration under 
conservative management he underwent surgery on the 
10th day of life. A long segment bowel necrosis with 
several perforations was found. Terminal ileum, right 
colon and the proximal transverse colon were resected, 
and enterostomy was performed. 
Culture of peritoneal fl uid, blood and stool 
remained negative. Feeding was started on the third 
postoperative day. On the 22nd day of life the baby 
had to undergo a second operation because of stomal 
stenosis. The stoma was closed at the age of fi ve 
months when he weighed 3000 g. At laparotomy we 
found colonic stenosis. At several levels a complete 
luminal obliteration of the remaining transverse colon 
and of the proximal part of the descending colon was 
seen and confi rmed by histological examination. The 
remaining transverse and proximal descending colons 
were resected and an anastomosis between ileum 
and descendent colon was created. The postoperative 
course was uneventful and the patient was discharged 
10 days after stoma closure.
Discussion
We presented dichorial diamniotic twins with a 
gestational age of 33+2 weeks who both developed 
necrotizing enterocolitis on the 6th day of life. Their 
mother was treated with venlafaxine, a nonselective 
serotonin reuptake inhibitor, throughout pregnancy 
until delivery. The question is whether therapy with 
venlafaxine during pregnancy is associated with a 
higher incidence of NEC or not. To date no clear 
association has been described in the literature, 
although neonatal withdrawal symptoms are well 
described.[3,4] Both twins required mechanical 
ventilation, although they had mild signs of hyaline 
membrane disease only. Surfactant therapy was not 
necessary and ventilatory requirements were moderate. 
It might be speculated that respiratory insuffi ciency 
could be secondary from maternal venlafaxine therapy. 
However only two cases of respiratory disease have 
been reported in association with venlafaxine treatment 
in adults.[5,6]
We found a case report describing two term 
neonates whose mothers were treated with a selective 
serotonin reuptake inhibitor (paroxetine) throughout 
pregnancy.[7] The babies developed NEC on the 3rd and 
4th day of life respectively. The uncommon occurrence 
of NEC in term neonates raises the question of whether 
serotonin reuptake inhibitors, selective or not, increase 
the risk for microcirculatory failure, possibly causing 
NEC. 
SSRI reduces platelet serotonin by inhibiting its 
uptake. This occasionally causes platelet dysfunction 
and bleeding.[8] Stiskal et al[7] speculated that 
increased platelet function as a rebound phenomenon 
may predispose the neonate to a hypercoagulable 
state. Since platelet activating factor plays a central 
role in the pathogenesis of NEC, disturbed platelet 
function is supposed to be mainly involved in disease 
progression.[9] 
Cocaine functions as a reuptake inhibitor 
of norepinephrine and dopamine amongst other 
neurotransmitters. Maternal cocaine use causes 
vasoconstriction that can result in placental abruption 
and perinatal stroke.[10] This assumption is mainly 
based on case reports, but the study of Heier et al[10] 
reported that 17% of full-term infants born to cocaine 
users had evidence of cortical infarction. Furthermore, 
cocaine exposure can lead to diminished gut blood-
supply and thereby contribute to the pathogenesis of 
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NEC. Two studies confi rmed the contributory role of 
cocaine abuse during pregnancy in the etiology, time of 
onset, and extent of neonatal NEC.[11,12]
Nonselective serotonin reuptake inhibitors as 
venlafaxine may have a similar mechanism of action 
to cocaine. It might be speculated that the inhibition of 
norepinephrine reuptake causes vasoconstriction in the 
intestine and hence ischemia that can lead to necrosis.
In the present case, prematurity certainly is an 
independent and essential risk factor for NEC. The 
correlation between enterocolitis and the venlafaxine 
therapy is speculative but possible and should be kept 
in mind when treating pregnant women and particularly 
when caring for newborns exposed to venlafaxine in 
utero.
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